In Chemotherapy for Lung Cancer, Sometimes Less is More
Open accessAbstract
Chemotherapy remains the backbone of care for patients with metastatic cancer and provides increasing hope for patients and their families as novel drug targets and therapeutic agents are discovered.Over the past decade, the therapeutic arsenal has markedly expanded, from nitrogen mustard and folic acid antagonists of the mid-20th century to the targeted regimens of "personalized" medicine today.In patients with metastatic disease, chemotherapy can slow disease progression, leading to prolonged survival, and palliate symptoms.Lung cancer remains the leading cause of cancerrelated mortality in the United States because of both the high prevalence of advanced disease at diagnosis and the low rate of cure of early-stage disease.Thus, many patients with metastatic non-small cell lung cancer (NSCLC) receive chemotherapy with the goal of prolonging life, relieving symptoms, and improving quality of life (QOL).Although chemotherapy can achieve these goals in selected patients with metastatic NSCLC and a good performance status (PS), it has a limited role in patients whose cancer has progressed through multiple lines of therapy and those with a poor PS (eg, ECOG 3 or 4).The response rates for patients with metastatic NSCLC treated with both a platinum and a taxane have been reported to be only 2% for third-line and 0% for fourth-line chemotherapy, 1 which is insufficient to provide a significant survival benefit. 2 Data regarding patients with NSCLC with a PS of 2 remains an unsolved issue, and carefully designed phase III trials are necessary to better define optimal treatment for patients with a borderline PS. [3][4][5] Thus, ASCO and NCCN guidelines have concluded that patients with a PS greater than 3 do not benefit from chemotherapy, except erlotinib for epidermal growth factor receptor mutation-positive patients and crizotinib for ALK-positive patients.[6][7][8] Despite these published national guidelines, the current trend is for patients with metastatic NSCLC to receive multiple lines of chemotherapy, even in the face of a declining or poor PS. [9][10][11][12] The continued discoveries of novel, targeted therapies are making it increasingly more challenging for patients and oncologists to forgo additional treatment, because of the hope of finding one that will lead to long-term progression-free survival.We all hope that the next erlotinib or crizotinib is on the horizon and that we will have effective targeted therapies available for all patients with metastatic NSCLC.This hope makes it difficult for oncologists to not offer that "one additional treatment" when faced with a patient whose condition is declining.However, the downside to this eternal optimism is that patients may receive additional lines of therapy with no clear benefit and with real potential harm.Although data have not conclusively demonstrated that prolonged chemotherapy may truly harm or even decrease survival in patients with metastatic cancer, one study examining Medicare patients with congestive heart failure or any 1 of 5 different malignancies supported the theory that hospice referral led to an improved survival, 13 and another study examining continued chemotherapy to the premortem period suggested that it only delays hospice referral and does not improve survival.14 A recently conducted prospective, randomized, single-institution clinical trial provides important insight into the question of prolonged chemotherapy administration in patients with incurable NSCLC.15 In this study, 151 patients with
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Palliative care has been associated with equal or longer survival in randomized and nonrandomized trials of patients with advanced cancer.
“In distinction from chemotherapy after the second-line setting, palliative care has been associated with equal103–106 or longer107–109 survival in randomized and nonrandomized110 trials of patients with advanced cancer.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482 · see citing works
Self-citationPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · see citing works
Bakitas, M., Lyons, K. D., Hegel, M. T., Balan, S., Brokaw, F. C., Seville, J., Hull, J. G., Li, Z., Tosteson, T. D., Byock, I. R., et al. (2009) · JAMA · doi:10.1001/jama.2009.1198 · Cited by 1,726 · see citing works
Christakis, N. A. (2000) · BMJ · doi:10.1136/bmj.320.7233.469 · Cited by 1,425 · see citing works
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111 · see citing works
Trends in the Aggressiveness of Cancer Care Near the End of Life
Earle, C. C., Neville, B. A., Landrum, M. B., Ayanian, J. Z., Block, S. D., & Weeks, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.136 · Cited by 990 · see citing works
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737 · see citing works
Radzikowska, E., Głaz, P., & Roszkowski, K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf187 · Cited by 424 · see citing works
Comparing Hospice and Nonhospice Patient Survival Among Patients Who Die Within a Three-Year Window
Connor, S. R., Pyenson, B. S., Fitch, K., Spence, C., & Iwasaki, K. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.10.010 · Cited by 422 · see citing works
Ho, T. H., Barbera, L. C., Saskin, R., Lu, H., Neville, B. A., & Earle, C. C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9897 · Cited by 411 · see citing works
Ettinger, D. S., Akerley, W., Borghaei, H., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K., Govindan, R., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0130 · Cited by 350 · see citing works
Physician factors associated with discussions about end‐of‐life care
Keating, N. L., Landrum, M. B., Rogers, S. O., Baum, S. K., Virnig, B. A., Huskamp, H. A., Earle, C. C., & Kahn, K. L. (2010) · Cancer · doi:10.1002/cncr.24761 · Cited by 345 · see citing works
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070002 · Cited by 332 · see citing works
Chemotherapy Use among Medicare Beneficiaries at the End of Life
Emanuel, E. J., Young‐Xu, Y., Levinsky, N. G., Gazelle, G. S., Saynina, O., & Ash, A. S. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00011 · Cited by 317 · see citing works
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Tanoue, L. T. (2011) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2011.02.002 · Cited by 286 · see citing works
Massarelli, E., André, F., Liu, D. D., Lee, J. J., Wolf, M., Fandi, A., Ochs, J., Chevalier, T. L., Fossella, F. V., & Herbst, R. S. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00308-2 · Cited by 200 · see citing works
Gridelli, C., Ardizzoni, A., Chevalier, T. L., Manegold, C., Perrone, F., Thatcher, N., van Zandwijk, N., Maïo, M. D., Martelli, O., & de Marinis, F. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh087 · Cited by 162 · see citing works
The effect on survival of continuing chemotherapy to near death
Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., & Earle, C. C. (2011) · BMC Palliative Care · doi:10.1186/1472-684x-10-14 · Cited by 157 · see citing works
Murillo, J. R., & Koeller, J. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1095 · Cited by 131 · see citing works
Discussions With Physicians About Hospice Among Patients With Metastatic Lung Cancer
Huskamp, H. A., Keating, N. L., Malin, J. L., Zaslavsky, A. M., Weeks, J. C., Earle, C. C., Teno, J. M., Virnig, B. A., Kahn, K. L., He, Y., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.127 · Cited by 127 · see citing works
Hospice Care and Survival among Elderly Patients with Lung Cancer
Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., Weeks, J. C., & Earle, C. C. (2011) · Journal of Palliative Medicine · doi:10.1089/jpm.2010.0522 · Cited by 111 · see citing works
Azzoli, C. G., Giaccone, G., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.091065 · Cited by 96 · see citing works
Langer, C. J., Li, S., Schiller, J. H., Tester, W. J., Rapoport, B. L., & Johnson, D. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9452 · Cited by 86 · see citing works
Patients rate physician communication about lung cancer
Nelson, J. E., Gay, E. B., Berman, A., Powell, C. A., Salazar‐Schicchi, J., & Wisnivesky, J. P. (2011) · Cancer · doi:10.1002/cncr.26152 · Cited by 84 · see citing works
Shanafelt, T. D., Loprinzi, C. L., Marks, R. S., Novotny, P. J., & Sloan, J. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.176 · Cited by 71 · see citing works
Self-citationChristakis, N. A., Lamont, E. B., Smith, J. L., & Parkes, C. M. (2000) · DigitalGeorgetown (Georgetown University Library) · Cited by 61 · see citing works
Azzoli, C. G., Baker, S., Temin, S., et al. (2010) · PubMed · doi:10.3779/j.issn.1009-3419.2010.03.15 · Cited by 58 · see citing works
Concealment of Information in Clinical Practice: Is Lying Less Stressful Than Telling the Truth?
Panagopoulou, E. P., Mintziori, G., Montgomery, A., Καπουκρανίδου, Δ., & Benos, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8751 · Cited by 56 · see citing works
Colby, W. H., Dahlin, C. M., Lantos, J. D., Carney, J., & Christopher, M. J. (2010) · HEC Forum · doi:10.1007/s10730-010-9128-3 · Cited by 42 · see citing works
Asahina, H., Sekine, I., Horinouchi, H., Nokihara, H., Yamamoto, N., Kubota, K., & Tamura, T. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.008 · Cited by 39 · see citing works
Incorporation of Crizotinib into the NCCN Guidelines
Riely, G. J., Chaft, J. E., Ladanyi, M., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0113 · Cited by 20 · see citing works
The art and science of prognosis in patients with advanced cancer
Steensma, D. P., & Loprinzi, C. L. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00290-2 · Cited by 18 · see citing works
Self-citationEffect of early palliative care on health care costs in patients with metastatic NSCLC.
Greer, J. A., McMahon, P. M., Tramontano, A. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6004 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- Saito A, Landrum MB, Neville B, et al. The effects on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.
- Connor SR, Pyenson B, Fitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238-246.
- Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment- induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:1966-1974.
Cited by
Sorted by citations
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850 · see citing works
Self-citation
- Authors
- Roeland, E., Loprinzi, C., Moynihan, T. J., Smith, T. J., & Temel, J.
- Affiliations
- Moores Cancer Center (US)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- Harvard University (US)
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2013-03
- Volume
- 11
- Issue
- 3
- Pages
- 232-235
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W1826306349
- Cited by
- 13
- References
- 33
- Citations by year
- 2023: 1 · 2019: 1 · 2017: 5 · 2016: 1 · 2015: 4 · 2013: 1
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the National Comprehensive Cancer Network (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- metastatic non-small cell lung cancer, chemotherapy, performance status, poor performance status, treatment de-escalation, quality of life, palliative care, targeted therapy, ECOG performance status, quality-adjusted life years, shared decision-making
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Palliative Care, Quality of Life, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
